HIMSS: Novarad, Dell debut vendor neutral archive

| | Health Exec | Informatics

NEW ORLEANS—Novarad and Dell have partnered to create Marz, a vendor neutral archive to store and manage patient data.

Marz combines Dell’s Unified Clinical Archive for on-premise or in the cloud data storage and management with Novarad’s viewer, iPad viewer or optional clinical viewer for image and report access.

With Marz, medical imaging data objects that adhere to standards-based IHE protocols of DICOM and non-DICOM file formats can be shared, exchanged and managed.

Marz’ open-standards format (XDS/XDSI protocol) makes it possible for facilities bring data together from disparate silos and store it in a non-proprietary format that enables data and images to be shared in a hospital information exchange, American Fork, Utah-based Novarad said in a release. 

 

 

Related Content

Alabama security breach exposes personal information of cardiologists, heart patients
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Best in KLAS 2024: New rankings for cardiovascular information systems, hemodynamic solutions
Best in KLAS 2024 rankings released, showcasing medical imaging IT systems
Cloud image storage for radiology is a growing trend in healthcare
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.